key: cord-0687342-qp4rhkaz
authors: Webb, Christine; Jones, Erika S.W.; Wearne, Nicola; Chetty, Dharshnee Rama; Blom, Dirk; Barday, Zunaid; Davidson, Bianca
title: COVID-19 associated graft loss from renal infarction in a kidney transplant recipient
date: 2021-02-01
journal: Kidney Int Rep
DOI: 10.1016/j.ekir.2021.01.009
sha: 6e0309721d8a2ddeefc357f867515e9656937ba7
doc_id: 687342
cord_uid: qp4rhkaz

nan

An increasing number of reports have recognized the contribution of COVID-19 to the development of acute kidney injury [AKI] and its impact on morbidity and mortality in hospitalised patients. 1 Of concern is the high rate of AKI reported in kidney transplant recipients infected with SARS-CoV-2 compared to the general population. 2 

We report on Mr. C.A, a 49-year-old male, who had his index presentation with chronic kidney disease [CKD] J o u r n a l P r e -p r o o f August 2020, in a public sector institution in South Africa, the mean age of the cohort (mean age 45.9 years) was lower but had similar comorbidities compared to international cohorts (mean age range 54-61years). The rationale is to overcome heparin resistance that occurs in COVID-19 due to increased levels of factor VII, von Willebrand factor and fibrinogen. A dosage of 1mg/kg/day for body weight less than 80kg and 0.5mg/kg 12 hourly for a weight of more than 80kg has been recommended. In kidney impairment the dose needs to be reduced by 50% for the former and to a once daily dose for the latter. S3 

The authors declare that they have obtained consent from the patient discussed in the report.

Graph of Creatinine trend 

Clinical course and mortality risk of severe COVID-19